| Literature DB >> 32986106 |
Elissa Ye1, Haoqi Sun1, Michael J Leone1, Luis Paixao1, Robert J Thomas2, Alice D Lam1, M Brandon Westover1.
Abstract
Importance: Dementia is an increasing cause of disability and loss of independence in the elderly population yet remains largely underdiagnosed. A biomarker for dementia that can identify individuals with or at risk for developing dementia may help close this diagnostic gap. Objective: To investigate the association between a sleep electroencephalography-based brain age index (BAI), the difference between chronological age and brain age estimated using the sleep electroencephalogram, and dementia. Design, Setting, and Participants: In this retrospective cross-sectional study of 9834 polysomnograms, BAI was computed among individuals with previously determined dementia, mild cognitive impairment (MCI), or cognitive symptoms but no diagnosis of MCI or dementia, and among healthy individuals without dementia from August 22, 2008, to June 4, 2018. Data were analyzed from November 15, 2018, to June 24, 2020. Exposure: Dementia, MCI, and dementia-related symptoms, such as cognitive change and memory impairment. Main Outcomes and Measures: The outcome measures were the trend in BAI when moving from groups ranging from healthy, to symptomatic, to MCI, to dementia and pairwise comparisons of BAI among these groups. Findings: A total of 5144 sleep studies were included in BAI examinations. Patients in these studies had a median (interquartile range) age of 54 (43-65) years, and 3026 (59%) were men. The patients included 88 with dementia, 44 with MCI, 1075 who were symptomatic, and 2336 without dementia. There was a monotonic increase in mean (SE) BAI from the nondementia group to the dementia group (nondementia: 0.20 [0.42]; symptomatic: 0.58 [0.41]; MCI: 1.65 [1.20]; dementia: 4.18 [1.02]; P < .001). Conclusions and Relevance: These findings suggest that a sleep-state electroencephalography-based BAI shows promise as a biomarker associated with progressive brain processes that ultimately result in dementia.Entities:
Year: 2020 PMID: 32986106 PMCID: PMC7522697 DOI: 10.1001/jamanetworkopen.2020.17357
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Definitions of Dementia, MCI, Symptomatic, Nondementia, and Healthy Groups and Exclusion Criteria
| Group | Criteria | No. | |
|---|---|---|---|
| Studies | Patients | ||
| Dementia | Using ≥1 dementia-related medication with a diagnosis containing any dementia keyword Diagnosis in the problem list containing any dementia keyword MoCA score ≤19 and no MoCA scores >27 after the sleep study MMSE score ≤25 | 96 | 81 |
| MCI | Diagnosis in the problem list containing any MCI keyword MoCA score 20-25 and no MoCA scores >27 after the sleep study | 55 | 44 |
| Symptomatic | Diagnosis containing any dementia or dementia-related keyword in the encounter diagnosis, problem list, and/or medical history | 1361 | 1075 |
| Nondementia | Does not belong to the dementia, MCI, or symptomatic group but may have a prior history of neurological or psychiatric disease in an encounter diagnosis, problem list, and/or medical history | 3632 studies | 3024 patients |
| Healthy | Subset of the nondementia group with no history of neurological or psychiatric disease in encounter diagnosis, problem list, and/or medical history | 2799 | 2336 |
| Excluded | Age <50 y Received a diagnosis for developmental delay, brain tumor, or neoplasm Received a diagnosis for stroke, brain injury or trauma, or seizure before sleep study | 4690 | 4053 |
Abbreviations: MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment.
Inclusion criteria are based on data entered in the medical record before the sleep study or at most 1 year after the sleep study unless otherwise stated. A patient was in a group if they met at least 1 of the inclusion criteria and did not meet any of the exclusion criteria. All groups except the healthy group were mutually exclusive. The healthy group was a subset of the nondementia group.
Dementia-related medications include aricept, donepezil, exelon, rivastigmine, memantine, namenda, namzaric, razadyne, and galantamine.
Dementia keywords were dementia and Alzheimer.
MCI keywords were MCI, mild cognitive impairment, and minimal cognitive impairment.
Dementia-related keywords were cognitive, memory, amnesia, agnosia, apraxia, aphasia, and mental.
Neurological or psychiatric disease included cerebral hemorrhage, Parkinsonism, mood disorder, psychotic disorder, intracranial hypertension, cerebral palsy, epilepsy, hydrocephalus, encephalopathy, multiple sclerosis, and delirium.
Figure 1. Brain Age Index (BAI) Across Dementia Groups
The dashed line indicates BAI = 0; MCI, mild cognitive impairment.
Figure 2. Associations of Neuropsychological Scores With Brain Age Index (BAI)
MoCA indicates Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination.
Figure 3. Regression Analysis of Potential Brain Age Index (BAI) Covariates With Dementia
Squares indicate coefficients of covariates; whiskers, 95% CIs; AHI, apnea-hypopnea index; BMI, body mass index; ESS, Epworth Sleepiness Scale; and PLMI, periodic limb movement index.
Figure 4. Association of Brain Age Index (BAI) Features and Dementia
B and C, features names describe related sleep stage, frequency band, measure, statistic, and channel location of the feature in order. All correlations shown are statistically significant. REM indicates rapid eye movement; N, non–REM stage.